The invention provides an application of a blood-derived enzymatic hydrolysis peptide in the preparation of a drug for inhibiting intestinal inflammation in animals. Specifically, pig blood is used as a raw material and purified through grinding, enzymolysis, suction filtration, centrifugation, ultrafiltration and other processes to obtain A biologically active peptide that has the effect of inhibiting intestinal inflammation in animals. The dried active peptide is in the form of thin layer, powder, powder with lighter color. The biologically active peptide has the effect of inhibiting intestinal inflammation judged by its inhibitory effect on mouse intestinal inflammation, and can be used as feed, feed additive, pharmaceutical auxiliary material, etc. The blood-derived enzymatic peptide for inhibiting intestinal inflammation of the present invention is non-toxic and has no side effects, does not remain in animals, and has significant economic and social contributions. The invention will promote the rapid development of active peptide biological products in the pharmaceutical industry and the feed industry.